Information Library

Cost control/reduction - Market Access

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • New York State's New PACeR Clinical Data Network

    August 5, 2010
    This briefing describes how the PACeR initiative has connected hospitals, physicians, patients' homes and pharmaceutical scientists to provide valuable insights into current, real-world medical practices.

  • A Blueprint for Clinical/Commercial Convergence

    August 5, 2010
    The development model for bio pharmaceutical companies must shift from two divergent paths to one that combines these two resources with market access strategy, information and capabilities.

  • QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE

    January 28, 2010 - Quintiles announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany.

  • Matthew Eberhart

    March 25, 2009
    Matt is a proven business-building executive with a strong track record of implementing successful business development initiatives for consulting healthcare companies in both North America and Europe.

Page 1 of 1 (4 results)

Subscribe to Email Based on Your Interests

Set preferences